samedan logo

 
 
spacer
home > pmps > spring 2019 > finding the right solution
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Finding the Right Solution

Demand from healthcare providers for treatments that are both clinically effective and commercially sustainable continues to put pressure on the pharmaceutical industry’s bottom line. This, combined with increasingly stringent regulations, means drug companies need to redouble efforts to ensure the economic delivery of treatments, and they need to accomplish this without jeopardising the quality or safety of their products. Optimising the use of packaging is an important step towards achieving these goals.

An Evolving Business Environment

A major challenge facing firms is that pharma manufacturing processes and supply chains now need to accommodate both generic, bulk-produced products and newer small batch options. With production becoming increasingly based on demand and pharma companies reducing inventory for many drug lines, a more agile supply chain is essential to ensure operational efficiency.

Addressing these issues will require closer collaboration with packaging suppliers with a deep understanding of material science and a proven ability to create cost-effective, innovative, and robust designs. Offering tailored designs that provide mandatory levels of security at a price that lowers costs is just one part of the process − they also need to be delivered quickly and economically.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Kori Anderson is Honeywell’s General Manager for Healthcare Packaging. At this year’s Pharmapack Expo, Honeywell launched a new pharmaceutical packaging solution, Aclar Accel.
spacer
Kori Anderson
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Immutep Announces GMP Manufacturing Process Developed for IMP761, a First-in-Class LAG-3 Agonist for Autoimmune Disease

SYDNEY, AUSTRALIA – 06 December 2022 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, announced today that a GMP compliant manufacturing process has been established for IMP761, its proprietary preclinical candidate for autoimmune diseases. The 200L scale attained by Northway Biotech, an end-to-end biopharmaceutical contract development and manufacturing organisation (CDMO), will ensure supply of IMP761 for IND-enabling studies and ensuing clinical trials.
More info >>

White Papers

Role of Comparators in Clinical Trial Supply

Clinical Services International

CSI analyses the role of comparators in different trial designs and offers expert advice on robust methodology for choosing the most appropriate comparators. Case studies provide real insight on how to choose comparators for rare diseases and oncology studies.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement